V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220022151 | 220005332 | 1.83 | 91 | Curative (C) | 2014-02-27 | 2014-02-27 | AML 19 TRIAL | Y | N | 220020646 | AML19 TRIAL |
| 220022152 | 220005340 | 1.94 | 66.75 | Disease modification (D) | 2014-08-29 | 2014-10-09 | AML 19 TRIAL | N | null | 220020654 | AML19 TRIAL |
| 220022153 | 220005353 | null | 100.1 | Palliative (P) | null | 2019-11-27 | Cytarabine Low Dose | N | N | 220020673 | CYTARABINE |
| 220022154 | 220012909 | 0 | 14.4 | Disease modification (D) | 2019-01-17 | 2019-01-19 | AML MyeChild 01 A Mitozantrone/Cytarabine | N | N | 220021161 | NOT MATCHED |
| 220022155 | 220017130 | 0 | 54.8 | Curative (C) | 2018-12-04 | 2018-12-04 | Enasidenib | N | N | 220021572 | NOT MATCHED |
| 220022156 | 220005718 | 1.55 | 59.8 | Adjuvant (A) | 2016-09-14 | 2019-02-22 | Hydroxycarbamide | N | N | 220021690 | HYDROXYCARBAMIDE |
| 220022157 | 220013007 | 1.59 | null | Curative (C) | 2018-12-09 | 2019-02-17 | CYTARABINE | N | N | 220021720 | CYTARABINE |
| 220022158 | 220005727 | 1.74 | 0 | Palliative (P) | 2018-11-21 | 2019-01-15 | Hydroxycarbamide | N | N | 220021721 | HYDROXYCARBAMIDE |
| 220022159 | 220005761 | 1.69 | 74 | Curative (C) | 2017-11-08 | 2017-11-08 | AML MyeChild 01 IT Cyt | N | N | 220021789 | NOT MATCHED |
| 220022160 | 220013067 | 0 | 12.4 | Curative (C) | 2019-10-14 | 2019-10-14 | AML Interim Guidelines FLA | N | null | 220021942 | NOT MATCHED |
| 220022161 | 220013134 | null | null | Palliative (P) | 2016-05-08 | 2016-05-10 | Cytarabine Low Dose | N | null | 220022212 | CYTARABINE |
| 220022162 | 220006072 | 1.46 | null | null | 2015-10-07 | 2015-10-07 | Hydroxycarbamide | null | null | 220022988 | HYDROXYCARBAMIDE |
| 220022164 | 220013319 | 1.53 | null | null | 2016-05-15 | 2017-04-01 | Cytarabine low (10to20mg/m2) IV/SC | N | N | 220023478 | CYTARABINE |
| 220022165 | 220017315 | 1.6 | null | Disease modification (D) | 2019-05-19 | 2019-05-19 | FBC Conditionining | N | N | 220023759 | NOT MATCHED |
| 220022166 | 220006273 | 1.43 | 62 | Curative (C) | 2014-03-26 | 2014-03-29 | AML Interim Guidelines FLA -Ida | 02 | N | 220023793 | NOT MATCHED |
| 220022167 | 220013388 | 1.65 | null | Curative (C) | 2018-08-27 | 2018-08-27 | Hydroxycarbamide | Y | N | 220023821 | HYDROXYCARBAMIDE |
| 220022168 | 220006298 | null | 0 | Curative (C) | 2019-08-19 | 2019-10-02 | Amsacrine + ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT) + BUSULFAN + CYTARABINE + FLUDARABINE | null | null | 220023866 | NOT MATCHED |
| 220022169 | 220006341 | 1.71 | 85 | Curative (C) | 2017-10-27 | 2017-10-28 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220024098 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220022170 | 220013514 | null | 93.6 | Curative (C) | 2018-11-05 | 2018-11-11 | AML 18 TRIAL | N | N | 220024528 | AML18 TRIAL |
| 220022171 | 220006499 | 1.84 | 96.1 | Curative (C) | 2019-09-05 | 2019-09-06 | Alemtuz+Fludara+Melphalan RIC MUD | 2 | N | 220024708 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220022173 | 220019550 | null | 97.7 | Curative (C) | 2017-03-05 | 2017-03-08 | AML 18 TRIAL | N | null | 220025121 | AML18 TRIAL |
| 220022174 | 220017472 | 1.62 | 79 | Curative (C) | 2016-05-20 | 2016-06-04 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220025945 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220022175 | 220006795 | 1.61 | 56 | Disease modification (D) | 2020-04-02 | 2020-04-02 | Dasatinib | N | N | 220026127 | DASATINIB |
| 220022176 | 220017491 | 1.78 | 98.2 | Curative (C) | 2017-04-21 | 2018-02-16 | Dasatinib | N | N | 220026128 | DASATINIB |
| 220022177 | 220007216 | null | 95.2 | null | 2015-08-14 | 2015-08-14 | AML18 PILOT TRIAL | N | N | 220027691 | PILOT TRIAL |
| 220022178 | 220007298 | 1.73 | 0 | null | 2018-05-15 | 2018-05-20 | Rituximab | N | N | 220028118 | RITUXIMAB |
| 220022179 | 220014018 | 1.55 | 49.9 | Curative (C) | 2013-09-17 | 2013-12-29 | AML 18 TRIAL | N | N | 220028136 | AML18 TRIAL |
| 220022180 | 220007321 | 0 | null | Curative (C) | 2015-12-06 | 2017-02-12 | Dasatinib | 2 | N | 220028203 | DASATINIB |
| 220022181 | 220014106 | 1.7 | null | Disease modification (D) | null | 2019-01-13 | Rituximab | 02 | N | 220028812 | RITUXIMAB |
| 220022182 | 220007513 | 1.63 | 61.3 | Disease modification (D) | 2015-05-12 | 2015-05-12 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | N | 220028990 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220022183 | 220007518 | 1.67 | 66.8 | Curative (C) | 2018-08-09 | 2018-08-09 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | null | 220028999 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220022184 | 220007549 | 1.79 | 61.6 | Curative (C) | 2018-09-05 | 2018-09-10 | AML 18 TRIAL | 1 | N | 220029118 | AML18 TRIAL |
| 220022185 | 220007597 | 1.58 | 55.2 | Curative (C) | 2019-06-07 | 2019-06-07 | AML18 PILOT TRIAL | N | N | 220029327 | PILOT TRIAL |
| 220022187 | 220007624 | 1.81 | 79 | Curative (C) | 2014-12-25 | 2014-12-25 | RUXOLITINIB | N | N | 220029445 | RUXOLITINIB |
| 220022188 | 220007749 | 1.8 | 68.8 | Curative (C) | 2017-06-26 | 2017-06-26 | ATG + Busulfan + Fludarabine | N | N | 220029817 | ATG + BUSULFAN + FLUDARABINE |
| 220022189 | 220007840 | 1.54 | 71.45 | Palliative (P) | 2016-03-20 | 2016-03-20 | ATG + Busulfan + Fludarabine | N | N | 220030144 | ATG + BUSULFAN + FLUDARABINE |
| 220022190 | 220007876 | 1.72 | 85.2 | Curative (C) | 2018-03-22 | 2018-03-22 | AML16 DA 3+8 | N | N | 220030225 | AML16 TRIAL |
| 220022191 | 220014350 | 0 | 0 | Curative (C) | 2014-12-08 | 2014-12-08 | BOSUTINIB | N | N | 220030353 | BOSUTINIB |
| 220022192 | 220007947 | 1.77 | 99 | Curative (C) | 2018-03-16 | 2018-03-22 | RUXOLITINIB | 02 | N | 220030435 | RUXOLITINIB |
| 220022193 | 220007962 | 0 | 86.8 | Palliative (P) | 2015-09-07 | 2015-10-30 | Triple Intrathecal | 01 | N | 220030471 | TRIPLE INTRATHECAL |
| 220022194 | 220017840 | 1.68 | null | Curative (C) | null | 2019-01-19 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220030475 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220022195 | 220007971 | 1.71 | 64 | Curative (C) | 2018-04-18 | 2018-05-26 | Methotrexate intrathecal | Y | N | 220030478 | METHOTREXATE INTRATHECAL |
| 220022196 | 220007983 | 1.67 | 88.9 | null | 2015-02-17 | 2015-02-24 | RUXOLITINIB | null | N | 220030497 | RUXOLITINIB |
| 220022197 | 220008089 | 1.63 | 65.4 | Disease modification (D) | 2015-02-16 | 2015-02-16 | FLAG | 2 | N | 220030766 | FLAG |
| 220022198 | 220008090 | null | 6.9 | Curative (C) | 2018-04-21 | 2018-10-15 | AML16 DA 2+5 | Y | N | 220030779 | AML16 TRIAL |
| 220022199 | 220008147 | 1.62 | 59.3 | Curative (C) | 2019-08-11 | 2019-08-15 | AML16 DA 3+10 | 2 | N | 220030955 | AML16 TRIAL |
| 220022200 | 220008241 | 1.65 | 85 | Curative (C) | 2015-06-02 | 2015-06-02 | AML16 DA 3+8 | 02 | N | 220031302 | AML16 TRIAL |
| 220022201 | 220008265 | null | 58.1 | Adjuvant (A) | 2018-04-22 | 2018-04-22 | Arsenic trioxide + Tretinoin | Y | N | 220031415 | ARSENIC TRIOXIDE + TRETINOIN |
| 220022202 | 220008324 | 1.55 | 65.1 | Curative (C) | 2014-01-19 | 2014-01-29 | FLUOROURACIL + OXALIPLATIN | 02 | N | 220031607 | GEMTUZUMAB OZOGAMICIN |
| 220022203 | 220008342 | 1.75 | 78 | Curative (C) | 2017-08-17 | 2017-08-17 | PONATINIB | Y | N | 220031681 | CLOFARABINE + CYTARABINE |